Friday 23rd February 2024 |
Text too small? |
For the third quarter ending 31 Dec 2023, Blis Technologies Limited (Blis) delivered revenue growth of 10% on the same period last year and a positive EBITDA result of $0.3m (unaudited).
Revenue growth came from a 12% increase in B2B revenue and a stronger than expected result for New Zealand and Amazon.
“Momentum continues to build around the successful execution of the refocused strategic plan. This has involved amongst other activities, working closely with business partners to sell more Blis product profitably into B2C and B2B channels.” said Scott Johnson, CEO.
Based on the latest customer sales forecasts and market feedback, guidance is for full year revenue to be about $11.0m, with EBITDA in the range of breakeven to $0.3m. This marks a return to profitability for the company.
Ends
For further information, please contact:
Scott Johnson
CEO
+64 21 488 831
About Blis Technologies Ltd
Delivering proven health benefits through evidence-based, advanced probiotics
Blis Technologies is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut. Combining innovation with evidence-based research and the highest quality production controls enables the delivery of probiotic solutions for specific health targets including throat health, halitosis (bad breath), immune support, teeth and gum health and skin health. BLIS® products are sold throughout New Zealand and in Asia, Europe and the USA. More information about Blis Technologies Ltd can be found at www.blis.co.nz.
No comments yet
May 15th Morning Report
Global Esports and game development landscape fast changing
PCT - Precinct FY24 Third Quarter Dividends
Just Life Group Limited buyback offer opens
Meridian Energy monthly operating report for April 2024
May 14th Morning Report
WCO - James Redmayne to resign from executive role
Fletcher Building Market Update
Devon Funds Morning Note - 13 May 2024
GTK - Half-Year Results Investor Briefing Details